Dietary guidance for lutein: consideration for intake recommendations is scientifically supported

Katherine M. Ranard1 · Sookyoung Jeon1 · Emily S. Mohn2 · James C. Griffiths3 · Elizabeth J. Johnson2 · John W. Erdman Jr.1,4

Published online: 17 November 2017
© The Author(s) 2017. This article is an open access publication

Abstract
Lutein, a yellow xanthophyll carotenoid found in egg yolks and many colorful fruits and vegetables, has gained public health interest for its potential role in visual performance and reducing the risk of age-related macular degeneration. The National Academies of Sciences, Engineering and Medicine’s recommended Dietary Reference Intakes (DRIs) focus on preventing deficiency and toxicity, but there is a budding interest in establishing DRI-like guidelines for non-essential bioactives, like lutein, that promote optimal health and/or prevent chronic diseases. Lupton et al. developed a set of nine criteria to determine whether a bioactive is ready to be considered for DRI-like recommendations. These criteria include: (1) an accepted definition; (2) a reliable analysis method; (3) a food database with known amounts of the bioactive; (4) cohort studies; (5) clinical trials on metabolic processes; (6) clinical trials for dose–response and efficacy; (7) safety data; (8) systematic reviews and/or meta-analyses; (9) a plausible biological rationale. Based on a review of the literature supporting these criteria, lutein is ready to be considered for intake recommendations. Establishing dietary guidance for lutein would encourage the consumption of lutein-containing foods and raise public awareness about its potential health benefits.

Keywords Lutein · Intake recommendations · Bioactives · Visual performance · Macular degeneration

Introduction
Lutein is a yellow xanthophyll carotenoid found in egg yolks and many fruits and vegetables, most notably leafy green vegetables like kale and spinach [1]. Lutein and its isomers, zeaxanthin and meso-zeaxanthin, are the only carotenoids that accumulate in the fovea of the human retina and constitute macular pigment (MP) [2]. The biological specificity for these carotenoids suggests that they have a role in the visual system. Increased dietary lutein/zeaxanthin intake raises serum concentrations and MP density. These markers are associated with improvements in visual function and a reduced risk of age-related macular degeneration (AMD) [3]. However, the average American adult consumes only ~1–2 mg lutein/day [4], which may not be enough to attain these health benefits.

There is growing enthusiasm for setting intake recommendations for non-essential dietary bioactives, such as lutein, that promote optimal health and/or prevent chronic diseases [5–7]. This is an extension of the traditional approach that is currently used for setting dietary reference intake (DRI) values, which focuses on preventing deficiency and toxicity of essential nutrients, e.g., vitamins and minerals. Establishing intake guidelines for lutein could encourage the consumption of lutein-containing foods and subsequently improve visual health.

Lupton et al. [8] developed a set of nine criteria to determine whether a bioactive has sufficient evidence to be considered for DRI-like recommendations. These criteria include: (1) an accepted definition; (2) a reliable analysis method; (3) a food database with known amounts of the
bioactive; (4) cohort studies; (5) clinical trials on metabolic processes; (6) clinical trials for dose–response and efficacy; (7) safety data; (8) systematic reviews and/or meta-analyses; (9) a plausible biological rationale.

Using the existing literature, we assessed how well lutein meets these nine criteria. This topic was briefly discussed by Johnson in 2014, but in this article, we elaborate on each criterion and include more recent evidence [3, 9]. It was not always possible to distinguish between lutein and its isomer zeaxanthin in our discussion, as many studies and dietary databases report a combined ‘lutein + zeaxanthin’ value. Lutein and zeaxanthin are both concentrated in the macula, are present in many of the same foods, and offer similar potential health benefits. Because of the close relationship between these isomers, we assert that a given criterion is fulfilled if the evidence supports either lutein alone or a combination of lutein/zeaxanthin.

**Commonly accepted definition**

**Criterion rationale**

With a commonly accepted definition, a database of efficacy can be created for the bioactive.

**How lutein meets this criterion**

Lutein is a yellow xanthophyll carotenoid with a singular molecular formula \( \text{C}_{40}\text{H}_{56}\text{O}_{2} \), an International Union of Pure and Applied Chemistry (IUPAC) name \((3\text{R},3\text{'R})-\beta,\beta\text{-carotene-3,3\text{'}}\text{-diol}\) , and a chemical abstracts services (CAS) registry number (127-40-2).

**Analysis method consistent with definition**

**Criterion rationale**

An established analysis method allows for comparison across laboratories and studies. Intake values can be measured to determine whether populations are meeting dietary recommendations.

**How lutein meets this criterion**

Lutein content in foods or tissues is commonly analyzed and quantified via high-performance liquid chromatography (HPLC). The National Institute of Standards and Technology (NIST) developed standard reference material (SRM) 968e, which includes lutein among other carotenoids, fat-soluble vitamins, and cholesterol in human serum [10]. SRM 968e can be used to validate methods for determining total lutein concentrations and/or quality assurance [10]. Several commonly used extraction and HPLC analysis methods include Epler et al. [11] and Sander et al. [12], which employ C18 and C30 analytical columns, respectively. The Yeum et al. [13] HPLC method (C30 analytical column) is also frequently used. The US Pharmacopeia (USP) has three quality monographs for (1) Lutein, (2) Lutein preparation, and (3) Lutein capsules. The USP Lutein Reference Standard [14] is used for testing lutein content. USP test methods use L3 porous silica columns that separate lutein and zeaxanthin (USP-NF 40-35) [15]. Some HPLC methods cannot separate lutein and its isomer zeaxanthin; this is one reason why ‘lutein + zeaxanthin’ are often reported together.

**Food databases**

**Criterion rationale**

Food databases indicate the quantity of the bioactive in the food supply. This information can be used to determine intake values.

**How Lutein meets this criterion**

Green leafy vegetables, egg yolks, and some orange/yellow fruits and vegetables are rich in lutein and zeaxanthin. The United States Department of Agriculture (USDA) Food Composition Database reports ‘lutein + zeaxanthin’ content in foods [1]. Others have analyzed foods such as fruits, vegetables, corn, and egg products specifically for lutein content [16].

**Prospective cohort studies**

**Criterion rationale**

The level of efficacy for a bioactive can be set based on dose–response data.

**How lutein meets this criterion**

At the highest percentile groupings of intake (\( \sim 3–5 \text{ mg/day} \)), lutein/zeaxanthin reduced the risk of early [17], intermediate [18], and advanced [19] AMD. Other cohort studies reviewed by Sabour-Pickett et al. show an inverse relationship between dietary or serum lutein/zeaxanthin and AMD [20].

**Clinical trials on digestion, absorption, activation, transport, and excretion**

**Criterion rationale**

Factors that impact metabolism of the bioactive can be determined to inform intake recommendations.
How lutein meets this criterion

Plasma kinetics studies have been conducted to show the absorption and excretion of lutein following a regimen of daily lutein supplements [21]. Similar to other carotenoids, the bioavailability of lutein increases when co-consumed with fat [22]. The food source and matrix also influence bioavailability: lutein from lutein-enriched eggs is more bioavailable than lutein from supplements or spinach [23]. Long-term lutein intake (15 weeks) also significantly increases the accumulation of lutein in tissues other than serum, such as buccal mucosa cells, adipose, and macula [24].

Both free and esterified forms of lutein are found in nature, though the majority of lutein in foods is in the free form [25]. Lutein esters are more stable and are often used in supplements. Free and esterified lutein are both bioavailable, but supplements containing free lutein may increase the serum/plasma lutein response more than supplements containing lutein esters [26]. Only free lutein is absorbed, so esterified lutein requires an additional ester-hydrolysis step in the small intestine; this could explain the different response between forms [26].

Many host-specific metabolic factors have also been studied, such as single-nucleotide polymorphisms (SNPs) in proteins important for intestinal absorption, transport, and metabolism of lutein. Variants in intestine-specific homeobox (ISX) and microsomal TG transfer protein (MTTP) are associated with differences in postprandial chylomicron lutein response in men [27, 28]. SNPs in ATP-binding cassette (ABC) transporters involved in cellular cholesterol efflux are associated with differences in serum/plasma lutein and zeaxanthin responses and postprandial chylomicron lutein response [28–30]. Some scavenger receptor class B type 1 (SCARB1) and CD36 SNP genotypes are associated with lower circulating levels of lutein [27, 30–32]. Several SNPs in SCARB1 and ABC transporters are associated with lower MP density in women [33].

Serum/plasma lutein concentrations and MP densities are influenced by variables related to both the source of lutein and the host. Our knowledge in this area, particularly related to host factors, is still evolving. With more research, we will be able to make more informed predictions about an individual’s response to dietary sources of lutein.

Clinical trials on efficacy and dose-response

Criterion rationale

These trials help set the efficacious intake level for the bioactive.

How Lutein meets this criterion

In clinical trials, lutein/zeaxanthin supplements consistently increase serum lutein/zeaxanthin concentrations and MP density [20]. In one trial, serum lutein concentrations increased linearly as lutein doses increased up to 20 mg/day; similar to other studies, serum concentrations plateaued after 2–3 weeks [34]. MP also followed a linear trend as doses of lutein increased [34]. Supplementing with macular carotenoids (including lutein) slows AMD progression in people with low lutein/zeaxanthin status [35] and improves measurements of visual performance, such as contrast sensitivity, visual acuity, and glare disability [36]. For reducing the risk of AMD, the efficacious intake level for lutein may be ~6 mg/day [37].

Safety data

Criterion rationale

Safety data are necessary, even if the bioactive is generally recognized as safe (GRAS).

How Lutein meets this criterion

American adults typically consume ~1–2 mg lutein/day [4]. A systematic risk assessment of lutein supplements used in placebo-controlled intervention trials was published in 2006 [38]. Based on this assessment, there is strong evidence that lutein is safe up to 20 mg/day [38]. Doses of lutein ranged from 8 to 40 mg/day and study durations have ranged from 7 days to 24 months. Only a few of the studies monitored possible adverse side effects, primarily through self-reporting. Subsequent to this publication, the AREDS2 trial reported no adverse effects—with the exception of some skin yellowing—from lutein and zeaxanthin supplementation (10 and 2 mg/day, respectively) over an average of 5 years in patients with intermediate AMD [35]. In a more recent case study, bilateral “foveal sparkles” were reported in an older woman who took a 20 mg/day lutein supplement for 8 years, along with exceptionally high dietary lutein intake [39]. Seven months after discontinuing the lutein supplement but continuing her dietary habits, the crystals resolved in the right eye, but not in the left eye.

Although safety data are available for lutein, future studies should evaluate chronic consumption of high lutein-containing supplements in specific populations.

Systematic reviews and meta-analyses

Criterion rationale

Systematic reviews and meta-analyses are needed to show efficacy of the bioactive.
How Lutein meets this criterion

Based on meta-analyses, there is a significant inverse association between lutein/zeaxanthin intake and risk of late AMD [40] and cataracts [41, 42]. Ma et al. reported that each 300 µg/day increment of dietary lutein/zeaxanthin reduces the risk of nuclear cataracts and posterior subcapsular cataracts by 3% [42]. Lutein/zeaxanthin supplementation is also significantly and dose-dependently related to improvements in visual acuity and contrast sensitivity [43]. Each 1 mg/day increase in lutein/zeaxanthin is associated with a favorable 0.003 reduction on a visual acuity scale (logarithm of minimum angle of resolution, logMAR), as well as improvements in contrast sensitivity of 0.010, 0.007, and 0.006 at the spatial frequencies of 3, 6, and 12 cycles/degree, respectively [43].

Plausible biological rationale

Criterion rationale

Although Lupton et al. [8] state that a biological explanation for efficacy is not required, this criterion is valuable to scientists and evaluators.

How Lutein meets this criterion

A lutein-binding protein (steroidogenic acute regulatory domain 3, StARD3) is located in the human macula [44]. MP, which increases in density with increased dietary lutein/zeaxanthin intake, may provide foveal photoprotection against damaging blue light [45]. In addition, lutein/zeaxanthin supplementation modulates the cell density profile of the foveal retinal pigment epithelium (RPE) [46]. This implicates MP in the development and/or maintenance of the RPE, which could thereby reduce susceptibility to macular degeneration.

Conclusions, challenges, and future directions

Lutein meets all nine criteria proposed by Lupton et al. [8] and should be considered for intake recommendations. Several criteria, namely those related to interindividual metabolic variables and safety data, may require additional attention to strengthen the case for lutein. As mentioned, lutein and zeaxanthin are often found together in foods/supplements and are sometimes jointly reported in food databases and clinical trials. MP optical density also reflects combined lutein/zeaxanthin/meso-zeaxanthin content, since all are present in the macula. These points are important to recognize as we consider setting intake recommendations for lutein.

The body of literature linking lutein to a reduced risk of AMD is richer than for the link between lutein and enhanced visual performance. However, using visual performance as the endpoint for intake recommendations would better align with the current dietary guidance for nutrients, which targets healthy populations.

Establishing intake recommendations for lutein would provide the public with yet another reason to eat more of the colorful fruits and vegetables lacking in our diets. Many consumers purchase products/supplements containing lutein, but without a recommendation, they may not be aware of the science that supports its role in health or know the appropriate intake level. The integration of specific intake recommendations for lutein (and potentially other bioactives) into nutrition public policy would also allow for easier evaluation of lutein intakes across populations; this would help assess whether populations are meeting recommendations [8].

Lupton et al. [8] made great strides by proposing an evaluative framework for bioactives, and we have provided supporting arguments that lutein is ready to be considered for DRI-like recommendations. As a next step, key policy makers (NIH, FDA, and others) should convene and discuss the strength of the supporting research, gaps in knowledge, and existing barriers and ways to overcome them. Establishing intake recommendations for lutein will be challenging, but doing so is critically important to Americans who are concerned about optimizing visual performance and reducing their risk of AMD.

Compliance with ethical standards

Conflict of interest K. M. Ranard, S. Jeon, E. S. Mohn, J. C. Griffiths, E. J. Johnson, and J. W. Erdman Jr. declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. US Department of Agriculture, Agricultural Research Service, Nutrient Data Laboratory. USDA national nutrient database for standard reference, release 28. Version current: September 2015, slightly revised May 2016. http://www.ars.usda.gov/ba/bhnrc/ndl. Accessed 12 Oct 2017
2. Bone RA, Landrum JT, Tarsis SL (1985) Preliminary identification of the human macular pigment. Vision Res 25:1531–1535
3. Johnson EJ (2014) Role of lutein and zeaxanthin in visual and cognitive function throughout the lifespan. Nutr Rev 72:605–612. https://doi.org/10.1111/nure.12133
4. Institute of Medicine (2000) Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. The National Academies Press, Washington, DC. https://doi.org/10.17226/9810
5. Biswaski HK, Erdman JW Jr, Hathcock J, Ellwood K, Beatty S, Johnson E, Marchioli R, Lauritzen L, Rice HB, Shao A, Griffiths JC (2013) Nutrient reference values for bioactives: what new approaches needed? A conference report. Eur J Nutr 52(Suppl 1):1–9. https://doi.org/10.1007/s00394-013-0503-0
6. National Academies of Sciences, Engineering, and Medicine (2017) Guiding principles for developing dietary reference intakes based on chronic disease, The National Academies Press, Washington, DC. https://doi.org/10.17226/24828
7. Yetley EA, MacFanlane AJ, Green-Finestone LS, Garza C, Ard JD, Atkinson SA, Bier DM, CarrigyUI, Harlan WR, Hattis D, King JC, Krewski D, O’Connor DL, Prentice RL, Rodricks JV, Wells GA (2017) Options for basing dietary reference intakes (DRIs) on chronic disease endpoints: report from a joint US-/Canadian-sponsored working group. Am J Clin Nutr 105:249S–285S. https://doi.org/10.3945/ajcn.116.139097
8. Lupton JR, Atkinson SA, Chang N, Fraga CG, Levy J, Messina M, Richardson DP, van Ommen B, Yang Y, Griffiths JC, Hathcock J (2014) Exploring the benefits and challenges of establishing a DRI-like process for bioactives. Eur J Nutr 53(Suppl 1):1–9. https://doi.org/10.1007/s00394-014-0666-3
9. Johnson EJ (2014) Response to letter from Peter P Hoppe: emerging science on lutein in the brain and why is nutrition so confusing? Cell 28:71–73
10. Thomas JB, Dueser DL, Mugenya IO, Phinne K, Sander LC, Sharpless KE, Sniegoski LT, Tai SS, Welch MJ, Yen JH (2012) Preparation and value assignment of standard reference material 968e fat-soluble vitamins, carotenoids, and cholesterol in human serum. Anal Bioanal Chem 402:749–762. https://doi.org/10.1007/s00216-011-4547-8
11. Epler KS, Ziegler RD, Craft NE (1993) Liquid chromatographic method for the determination of carotenoids, retinoids and tocopherols in human serum and in food. J Chromatogr 619:37–48
12. Sander LC, Sharpless KE, Craft NE, Wise SA (1994) Development of engineered stationary phases for the separation of carotenoid isomers. Anal Chem 66:1667–1674
13. Yeum KJ, Booth SL, Sadowski JA, Liu C, Tang G, Kinsky NL, Russell RM (1996) Human plasma carotenoid response to the ingestion of controlled diets high in fruits and vegetables. Am J Clin Nutr 64:594–602
14. US Pharmacopeia (2017) Lutein reference standard. US Pharmacopeial Convention. http://static.usp.org/pdf/EN/refStandardStandards/certificates/s170804-r045e0.pdf. Accessed 30 Oct 2017
15. US Pharmacopeia (2017) The United States Pharmacopeia 40 and the National Formulary 35 (USP40-NF35): Lutein monograph; Lutein Capsules monograph; Lutein Preparations monograph. http://www.uspharmacist.com/articles/65310224/407842235
16. Perry A, Rasmussen H, Johnson EJ (2009) Xanthophyll (lutein, zeaxanthin) content in fruits, vegetables and corn and egg products. J Food Compos Anal 22:9–15
17. Ho L, van Leeuwen R, Witteman JC, van Duijn CM, Uitterlinden AG, Hofman A, de Jong PT, Vingerling JR, Klaver CC (2011) Reducing the genetic risk of age-related macular degeneration with dietary antioxidants, zinc, and omega-3 fatty acids: the Rotterdam study. Arch Ophthalmol 129:758–766. https://doi.org/10.1001/archophthalmol.2011.141
18. Moeller SM, Parekh N, Tinker L, Ritenbaugh C, Blodi B, Wallace RB, Mares JA, Group CRS (2006) Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the carotenoids in age-related eye disease study (CAREDS): ancillary study of the Women’s Health Initiative. Arch Ophthalmol 124:1151–1162. https://doi.org/10.1001/archophthalmol.124.8.11151
19. Wu J, Cho E, Willett WC, Sastry SM, Schaumberg DA (2015) Intakes of lutein, zeaxanthin, and other carotenoids and age-related macular degeneration during 2 decades of prospective follow-up. JAMA Ophthalmol:1–10. https://doi.org/10.1001/jamaophthalmol.2015.3590
20. Sabour-Pickett S, Nolan JM, Loughman J, Beatty S (2012) A review of the evidence germane to the putative protective role of the macular carotenoids for age-related macular degeneration. Mol Nutr Food Res 56:270–286. https://doi.org/10.1002/mnfr.201100219
21. Thurham DI (2007) Macular zeaxanthins and lutein—a review of dietary sources and bioavailability and some relationships with macular pigment optical density and age-related macular disease. Nutr Res Rev 20:163–179. https://doi.org/10.1017/S0954422407842235
22. Unlu NZ, Bohn T, Clinton SK, Schwartz SJ (2005) Carotenoid absorption from salad and salsa by humans is enhanced by the addition of avocado or avocado oil. J Nutr 135:431–436
23. Chung HY, Rasmussen HM, Johnson EJ (2004) Lutein bioavailability is higher from lutein-enriched eggs than from supplements and spinach in men. J Nutr 134:1887–1893
24. Johnson EJ, Hammond BR, Yeum KJ, Qin J, Wang XD, Castaneda C, Snodderly DM, Russell RM (2000) Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density. Am J Clin Nutr 71:1555–1562
25. Breithaupt DE, Bamedi A (2001) Carotenoid esters in vegetables and fruits: a screening with emphasis on beta-cryptoxanthin esters. J Agric Food Chem 49:2064–2070
26. Norkus EP, Norkus KL, Dharmarajan TS, Schierle J, Schalch W (2010) Serum lutein response is greater from free lutein than from esterified lutein during 4 weeks of supplementation in healthy adults. J Am Coll Nutr 29:575–585
27. Borel P, de Edelenyi FS, Vincent-Baudry S, Malezet-Desmoulin C, Margotat A, Lyan B, Gorram JD, Meunier N, Drouault-Holowacz S, Bieuvete S (2011) Genetic variants in BCM01 and CD36 are associated with plasma lutein concentrations and macular pigment optical density in humans. Ann Med 43:47–59. https://doi.org/10.3109/07853890.2010.3317575
28. Borel P, Desmarchelier C, Nowicki M, Bott R, Morange S, Lesavre N (2014) Interindividual variability of lutein bioavailability in healthy men: characterization, genetic variants involved, and relation with plasma lutein concentration. Am J Clin Nutr 100:168–175. https://doi.org/10.3945/ajcn.114.085720
29. Herron KL, McGraw MM, Waters D, Lofgren IE, Clark RM, Ordovas JM, Fernandez ML (2006) The ABCG5 polymorphism contributes to individual responses to dietary cholesterol and carotenoids in eggs. J Nutr 136:1161–1165
30. Meyers KJ, Mares JA, Igo RP Jr, Truitt B, Liu Z, Millen AE, Klein M, Johnson EJ, Engelman CD, Kariki CK, Blodi B, Gehrs K, Tinker L, Wallace R, Robinson J, LeBlanc ES, Sarto G, Bernstein PS, Santovini J, Eyengar SK (2014) Genetic evidence for role of carotenoids in age-related macular degeneration in the carotenoids in age-related eye disease study (CAREDS). Invest Ophthalmol Vis Sci 55:587–599. https://doi.org/10.1167/iovs.13-13216
31. Borel P, Moussa M, Reboul E, Lyan B, Defoort C, Vincent-Baudry S, Mailiot M, Gastaldi M, Darmon M, Portugal H, Plantell R, Lairot D (2007) Human plasma levels of vitamin E and carotenoids are associated with genetic polymorphisms in genes involved in lipid metabolism. J Nutr 137:2653–2659
32. McKay GJ, Loane E, Nolan JM, Patterson CC, Meyers KJ, Mares JA, Yonova-Doing E, Hammond CJ, Beatty S, Silvestri G (2013) Investigation of genetic variation in scavenger receptor class B, member 1 (SCARB1) and association with serum carotenoids. Arch Ophthalmo...
33. Meyers KJ, Johnson EJ, Bernstein PS, Iyengar SK, Engelman CD, Karki CK, Liu Z, Igo RP Jr, Truitt B, Klein ML, Snodderly DM, Blodi BA, Gehrs KM, Sarto GE, Wallace RB, Robinson J, LeBlanc ES, Hageman G, Tinker L, Mares JA (2013) Genetic determinants of macular pigments in women of the carotenoids in age-related eye disease study. Invest Ophthalmol Vis Sci 54:2333–2345. https://doi.org/10.1167/iovs.12-10867

34. Bone RA, Landrum JT (2010) Dose-dependent response of serum lutein and macular pigment optical density to supplementation with lutein esters. Arch Biochem Biophys 504:50–55. https://doi.org/10.1016/j.abb.2010.06.019

35. Age-Related Eye Disease Study 2 Research G (2013) Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA 309:2005–2015. https://doi.org/10.1001/jama.2013.4997

36. Mares J (2016) Lutein and zeaxanthin isomers in eye health and disease. Annu Rev Nutr 36:571–602. https://doi.org/10.1146/annurev-nutr-071715-051110

37. Seddon JM, Ajani UA, Sperduto RD, Hiller R, Blair N, Burton TC, Farber MD, Gragoudas ES, Haller J, Miller DT et al (1994) Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye disease case-control study group. JAMA 272:1413–1420

38. Shao A, Hathcock JN (2006) Risk assessment for the carotenoids lutein and lycopene. Regul Toxicol Pharmacol 45:289–298. https://doi.org/10.1016/j.yrtph.2006.05.007

39. Choi RY, Chortkoff SC, Gorusupudi A, Bernstein PS (2016) Crystalline maculopathy associated with high-dose lutein supplementation. JAMA Ophthalmol 134:1445–1448. https://doi.org/10.1001/jamaophthalmol.2016.4117

40. Ma L, Dou HL, Wu YQ, Huang YM, Huang YB, Xu XR, Zou ZY, Lin XM (2012) Lutein and zeaxanthin intake and the risk of age-related macular degeneration: a systematic review and meta-analysis. Br J Nutr 107:350–359. https://doi.org/10.1017/S0007114511004260

41. Liu XH, Yu RB, Liu R, Hao ZX, Han CC, Zhu ZH, Ma L (2014) Association between lutein and zeaxanthin status and the risk of cataract: a meta-analysis. Nutrients 6:452–465. https://doi.org/10.3390/nu6010452

42. Ma L, Hao ZX, Liu RR, Yu RB, Shi Q, Pan JP (2014) A dose-response meta-analysis of dietary lutein and zeaxanthin intake in relation to risk of age-related cataract. Graefes Arch Clin Exp Ophthalmol 252:63–70. https://doi.org/10.1007/s00417-013-2492-3

43. Liu R, Wang T, Zhang B, Qin L, Wu C, Li Q, Ma L (2014) Lutein and zeaxanthin supplementation and association with visual function in age-related macular degeneration. Invest Ophthalmol Vis Sci 56:252–258. https://doi.org/10.1167/iovs.14-15553

44. Li B, Vachali P, Frederick JM, Bernstein PS (2011) Identification of StARD3 as a lutein-binding protein in the macula of the primate retina. Biochemistry 50:2541–2549. https://doi.org/10.1021/bi101906y

45. Barker FM, 2nd, Snodderly DM, Johnson EJ, Schalch W, Koeckcke W, Gerss J, Neuringer M (2011) Nutritional manipulation of primate retinas, V: effects of lutein, zeaxanthin, and n-3 fatty acids on retinal sensitivity to blue-light-induced damage. Invest Ophthalmol Vis Sci 52:3934–3942. https://doi.org/10.1167/iovs.10-5898

46. Leung YY, Sandstrom MM, Zucker CL, Neuringer M, Snodderly DM (2004) Nutritional manipulation of primate retinas, II: effects of age, n-3 fatty acids, lutein, and zeaxanthin on retinal pigment epithelium. Invest Ophthalmol Vis Sci 45:3244–3256. https://doi.org/10.1167/iovs.02-1233